Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec:1:159-162.
doi: 10.1016/j.ijregi.2021.11.003. Epub 2021 Nov 18.

Clinical outcomes of pediatric COVID-19 in a tertiary care center in Bangkok, Thailand

Suvaporn Anugulruengkitt  1   2 , Sirinya Teeraananchai  3 , Napaporn Chantasrisawad  1   2   4 , Pathariya Promsena  2 , Watsamon Jantarabenjakul  1   2   4 , Thanyawee Puthanakit  1   2
Affiliations

Clinical outcomes of pediatric COVID-19 in a tertiary care center in Bangkok, Thailand

Suvaporn Anugulruengkitt et al. IJID Reg. 2021 Dec.

Abstract

Objective: To describe the clinical characteristics and outcomes of pediatric COVID-19 in Thailand, where favipiravir is the mainstay of antiviral treatment.

Methods: We conducted a hospital based observational cohort study of COVID-19 among children. The study included children (age <15 years) with confirmed positive reverse transcriptase-polymerase chain reaction for SARS-CoV-2 from nasopharyngeal swab.

Results: From April to July 2021, 416 cases with a median age of 7.1 (interquartile range 2.7-11.6) years were included in the study. The spectrum of disease included 82 (20%) asymptomatic, 232 (56%) mild and 102 (24%) with pneumonia. Abnormal chest x-ray findings included ground-glass opacities (46%), focal infiltrations (27%), perihilar opacities (19%), reticular infiltrations (15%) and other non-specific findings (4%). Only 12 children (3%) required oxygen support. Favipiravir was prescribed to 129 children (31%); 102 patients with pneumonia and 27 patients at risk for disease progression. Pneumonia was more common in age <3 years compared with those aged 3-<12 years (adjusted odds ratio (aOR) 0.30, 95% CI 0.17-0.52), 12-15 years (aOR 0.40, 95% CI 0.21-0.77) and in patients with comorbidities (aOR 2.36, 95% CI 1.09-5.12).

Conclusions: One-fourth of pediatric COVID-19 patients had pneumonia, but few required oxygen support. Off-label use of Favipiravir in pediatric COVID-19 patients in a recent outbreak in Bangkok is reported.

Keywords: COVID-19; Children; Favipiravir; Pneumonia; SARS-CoV-2.

PubMed Disclaimer

References

    1. Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil. Available at: https://www.appilitherapeutics.com/newsfeed/Appili-Therapeutics-Inc.-Exp.... Accessed Sep 1, 2021.
    1. Delahoy MJ, Ujamaa D, Whitaker M, et al. Hospitalizations Associated with COVID-19 Among Children and Adolescents - COVID-NET, 14 States, March 1, 2020-August 14, 2021. MMWR. 2021;70(36):1255–1260. doi: 10.15585/mmwr.mm7036e2. - DOI - PMC - PubMed
    1. Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018;153:85–94. doi: 10.1016/j.antiviral.2018.03.003. - DOI - PubMed
    1. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6) doi: 10.1542/peds.2020-0702. - DOI - PubMed
    1. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088–1095. doi: 10.1111/apa.15270. - DOI - PMC - PubMed